Skip to content

PTHS PTHS Shares issued for cash under equity line of credit

Shares issued for cash under equity line of credit at other companies

OS Therapies logo
OS TherapiesOSTX
$568.24K
OS Therapies logo
OS TherapiesOSTX
$568.24K
DeFi Development Corp. Common Stock logo
DeFi Development Corp. Common StockDFDV
$5.06M
OS Therapies logo
OS TherapiesOSTX
$568.24K
Helen Of Troy logo
Helen Of TroyHELE
$1K
Spectral AI, Inc. logo
Spectral AI, Inc.MDAI
$2.7M

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept pths:ProceedsFromSharesIssuedForCashUnderEquityLineOfCredit.

The official record: PTHS’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's shares issued for cash under equity line of credit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's shares issued for cash under equity line of credit?
PTHS (PTHS) reported shares issued for cash under equity line of credit of $0 in Q4 2025.
How has PTHS's shares issued for cash under equity line of credit changed year-over-year?
PTHS's shares issued for cash under equity line of credit decreased by 100.0% year-over-year, from $20.75K to $0.
What does shares issued for cash under equity line of credit mean?
Reflects the cash inflows generated from the sale of equity securities through a pre-arranged equity line of credit facility. This serves as a key liquidity indicator for clinical-stage companies relying on periodic capital raises to fund ongoing research and development.